Listed by the USPTO as GIAMMONA, FRANCESCA FILIPPA
Tech Center 1600 • Art Units: 1637 1671 1681 1682
This examiner grants 37% of resolved cases
GIAMMONA, FRANCESCA FILIPPA works in Technology Center 1600 and Art Unit 1637. The profile contains 83 resolved cases, with an allowance rate of 37.3% and a median of 1482 days to allowance. The interview lift is 58.8%, making interviews a prominent feature of the observed allowance pattern.
The principal companies are Natera Inc., GEN-PROBE Incorporated, and Illumina Inc. The leading firms are WILSON SONSINI GOODRICH & ROSATI, PABST PATENT GROUP LLP, and BIOTECH BEACH LAW PC. The combination of a lower allowance rate, extended median timeline, and substantial interview lift suggests that practitioners should give particular attention to interview preparation and claim-development strategy. The company and firm affiliations identify the biotechnology contexts most represented in the record.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18027087 | RANDOM INSERTION GENOME RECONSTRUCTION | Final Rejection | GOOGLE LLC |
| 17925693 | METHODS FOR DETECTION OF DONOR-DERIVED CELL-FREE DNA | Non-Final OA | Natera, Inc. |
| 17413464 | METHODS FOR ANALYSIS OF CIRCULATING CELLS | Non-Final OA | Natera, Inc. |
| 19326091 | COMPOSITIONS AND METHODS OF MAKING GENE EXPRESSION LIBRARIES | Non-Final OA | 10x Genomics, Inc. |
| 17789131 | PRIMER SET AND METHOD FOR DETECTING TARGET NUCLEIC ACID USING SAME | Final Rejection | KANEKA CORPORATION |
| 18629922 | Kaposi sarcoma associated herpesvirus gene function | Non-Final OA | The Regents of the University of California |
| 18248121 | MASSIVELY SCALABLE VIRAL TESTING AND ASYMPTOMATIC SURVEILLANCE | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17421677 | RAPID REVERSE TRANSCRIPTION QUANTITATIVE POLYMERASE CHAIN REACTION | Final Rejection | Northwestern University |
| 18027561 | METHOD FOR PREDICTION OF RECURRENCE OR PROGNOSIS OF DIABETIC FOOT ULCER BY USING SPECIFIC METHYLATION OF GENE | Final Rejection | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION |
| 17905784 | NOVEL NUCLEIC ACID TEMPLATE STRUCTURE FOR SEQUENCING | Non-Final OA | Roche Sequencing Solutions, Inc. |
| 17619116 | DNA METHYLATION BIOMARKERS FOR CANCER DIAGNOSING AND TREATMENT | Final Rejection | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA |
| 17441526 | Compositions and Methods for Detecting Group A Streptococcus | Non-Final OA | Gen-Probe Incorporated |
| 17382568 | DETECTION OF DRUG-RESISTANT MYCOPLASMA GENITALIUM | Non-Final OA | GEN-PROBE INCORPORATED |
| 18248285 | METHODS AND MEANS FOR AMPLIFICATION-BASED QUANTIFICATION OF NUCLEIC ACIDS | Final Rejection | Imperial College Innovations Limited |
| 18190809 | SYSTEMS AND METHODS OF SEQUENCING POLYNUCLEOTIDES | Non-Final OA | Illumina, Inc. |
| 18000666 | SELECTING APTAMERS USING SEQUENCING | Non-Final OA | Illumina, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy37.3% of resolved applications examined by Francesca Filippa Giammona were allowed (83 resolved cases), compared with 45.4% across Art Unit 1637 over the last five years.
This examiner's interview lift is +58.8 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Francesca Filippa Giammona took 1,482 days on average from filing to allowance.
Francesca Filippa Giammona examines applications in Art Unit 1637 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
